Blood Group Typing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031

The Global Blood Group Typing Market is projected to expand from USD 2.42 Billion in 2025 to USD 4.05 Billion by 2031, achieving a CAGR of 8.94%. Blood group typing is a diagnostic procedure utilized to identify specific ABO and Rh antigens on red blood cells, ensuring serological compatibility before transfusion. The market is primarily driven by the increasing global prevalence of chronic hematologic disorders and a rising number of trauma cases that necessitate immediate blood replacement. Additionally, the growing volume of complex surgical procedures requires rigorous pre-transfusion screening to ensure patient safety, thereby sustaining strong demand for accurate typing reagents and automated assay systems across healthcare facilities.

However, the market encounters significant obstacles due to the volatility of blood supplies, which disrupts consistent testing workflows. A declining donor base places immense pressure on inventory management, frequently resulting in supply shortages that complicate the efficient use of typing resources. For example, the American Red Cross reported that the national blood inventory fell by more than 25 percent in July 2024 due to persistent donor shortages. This instability in the supply chain creates operational challenges that can impede the steady growth of the blood group typing market.

Market Drivers

Technological innovations in automated and molecular blood typing solutions are fundamentally reshaping the market by improving diagnostic precision and operational efficiency. Laboratories are increasingly transitioning from manual methods to fully automated platforms, which minimize human error and standardize ABO/Rh typing results. This shift is financially evident in the performance of major industry players supplying these critical diagnostic systems. For instance, Grifols reported in their 'Full Year 2024 Results' in February 2025 that their Blood Typing Solutions division achieved double-digit growth in key international markets, a surge largely attributed to the accelerated adoption of these automated instruments. Such technologies not only enhance speed but also provide the high-volume processing capabilities necessary for maintaining steady workflows in large-scale blood centers.

Simultaneously, the rising incidence of trauma cases requiring transfusion acts as a primary catalyst for market expansion. Emergency medicine depends heavily on immediate and precise blood grouping to prevent fatal transfusion reactions during critical care interventions. The demand for typing reagents correlates directly with the volume of patients entering trauma centers who require substantial blood support. As noted by the American Red Cross in their May 2025 'Trauma Season Blood Donation' press release, approximately 25 percent of all trauma patients require blood transfusions, driving an urgent need for compatible blood products. This consistent clinical demand underpins the stability of the consumables sector; for example, QuidelOrtho highlighted in their February 2025 'Q4 and Full Year 2024 Financial Results' that the company's Transfusion Medicine business achieved over 90 percent recurring revenue in 2024, underscoring the essential nature of blood typing in modern healthcare.

Market Challenges

The persistent volatility of blood supplies functions as a substantial restraint on the blood group typing market by directly limiting the volume of diagnostic procedures performed. When donor participation declines, blood centers and hospitals face immediate inventory deficits, necessitating a reduction in the number of pre-transfusion tests conducted. This direct correlation means that a shrinking donor base results in lower utilization rates for typing reagents and automated assay platforms. Consequently, laboratories are unable to maintain consistent testing throughput, leading to idle equipment capacity and a reduced frequency of procurement for essential diagnostic consumables.

These supply chain disruptions introduce operational instability that hinders long-term market planning and expansion. The unpredictability of donor turnout forces healthcare facilities to manage inventories conservatively, restricting the steady consumption of typing products. For instance, NHS Blood and Transplant reported in July 2024 that national stocks of O Negative blood dropped to just 1.6 days, requiring clinical staff to restrict usage to emergency cases. Such critical shortages stall market growth by lowering the overall demand for typing services and preventing the continuous revenue generation necessary for industry development.

Market Trends

There is a growing focus on customized assays for rare blood group identification, prioritizing the needs of chronically transfused patients who require precise phenotypic matching. Standard serological tests are often insufficient for preventing alloimmunization in complex cases, such as those involving sickle cell disease, prompting the adoption of extensive donor screening programs. This clinical shift enables blood centers to manage diverse inventories more effectively and ensure compatibility for recipients who are difficult to match. According to the American Red Cross's September 2025 'Sickle Cell Awareness Month' press release, the organization supported this demand for precision by providing more than 300,000 sickle cell trait screenings, a critical measure for identifying compatible donors with rare antigen profiles.

Concurrently, the expansion of Human Leukocyte Antigen (HLA) typing applications is diversifying the operational scope of the blood group typing market. Laboratories are extending their diagnostic capabilities beyond traditional red cell antigens to include histocompatibility testing for organ and stem cell transplantation, utilizing advanced genomic platforms for high-resolution matching. This integration of transplant diagnostics into blood bank workflows represents a strategic broadening of services to support complex clinical interventions. As noted by Werfen in their March 2025 'Non-Financial Information Statement for 2024', the company’s dedicated Transplant division secured a 12 percent share of the market, reflecting the increasing industrial emphasis on these specialized typing solutions.

Key Players Profiled in the Blood Group Typing Market

• Thermo Fisher Scientific Inc.
• Danaher Corporation
• Illumina, Inc.
• Immucor, Inc.
• CareDx Inc.
• Mesa Laboratories, Inc.
• Bio-Rad Laboratories, Inc.
• Merck KGaA
• AliveDx Suisse SA
• QuidelOrtho Corporation

Report Scope

In this report, the Global Blood Group Typing Market has been segmented into the following categories:

Blood Group Typing Market, by Product:

• Consumables
• Instruments
• Services

Blood Group Typing Market, by Technique:

• PCR-Based and Microarray Techniques
• Assay-Based Techniques
• Massively Parallel Sequencing
• Others

Blood Group Typing Market, by Test Type:

• Antibody Screening
• HLA Typing
• ABO Blood Tests
• Cross-Matching Tests
• Antigen Typing

Blood Group Typing Market, by End User:

• Hospitals
• Clinical Laboratories
• Blood Banks
• Other End Users

Blood Group Typing Market, by Region:

• North America
• Europe
• Asia-Pacific
• South America
• Middle East & Africa

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Blood Group Typing Market.

Available Customization

The analyst offers customization according to your specific needs. The following customization options are available for the report:

• Detailed analysis and profiling of additional market players (up to five).

This product will be delivered within 1-3 business days.